Findings

What do systematic reviews say?

49 questions · 49 findings · 7 reviews · Epilepsy

No studies found 12 · 24.5%GRADE not reported 0 · 0%Very low 15 · 30.6%Low 5 · 10.2%Moderate 11 · 22.4%High 6 · 12.2%

50% or greater reduction in seizure frequency · patients with AD and epileptic seizures

It is very uncertain whether levetiracetam changes reduction in seizure frequency of 50% or more compared with lamotrigine (very low certainty).

1 finding from 1 review

Treatment of epilepsy for people with Alzheimer's disease 2021 · Cochrane Headline outcomes only
RR 1.21 [0.84, 1.75]
1 study · 67 participants
Very low

Proportion with seizure freedom in dominantly inherited AD · patients with AD and epileptic seizures

The review found no eligible studies for this question.

1 finding from 1 review

Treatment of epilepsy for people with Alzheimer's disease 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Change in cognition · patients with AD and epileptic seizures

1 finding from 1 review

Treatment of epilepsy for people with Alzheimer's disease 2021 · Cochrane Headline outcomes only
no estimate extracted
1 study · 67 participants
Very low

Change in neuropsychiatric symptoms · patients with AD and epileptic seizures

1 finding from 1 review

Treatment of epilepsy for people with Alzheimer's disease 2021 · Cochrane Headline outcomes only
no estimate extracted
1 study · 67 participants
Very low

Improvement in quality of life · patients with AD and epileptic seizures

The review found no eligible studies for this question.

1 finding from 1 review

Treatment of epilepsy for people with Alzheimer's disease 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Seizure freedom · absence seizures in children and adolescents

1 finding from 1 review

Ethosuximide, sodium valproate or lamotrigine for absence seizures in children and adolescents 2021 · Cochrane Headline outcomes only
no estimate extracted
4 studies · 365 participants
Moderate

80% or greater reduction in seizure frequency ‐ not reported · absence seizures in children and adolescents

It is very uncertain whether ethosuximide changes 80% or greater reduction in seizure frequency compared with valproate (very low certainty).

1 finding from 1 review

Ethosuximide, sodium valproate or lamotrigine for absence seizures in children and adolescents 2021 · Cochrane Headline outcomes only
RR 0.7 [0.19, 2.59]
1 study · 29 participants
Very low

50% or greater reduction in seizure frequency · absence seizures in children and adolescents

1 finding from 1 review

Ethosuximide, sodium valproate or lamotrigine for absence seizures in children and adolescents 2021 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 49 participants
Low

Normalisation of the EEG ‐ not reported · absence seizures in children and adolescents

The review found no eligible studies for this question.

1 finding from 1 review

Ethosuximide, sodium valproate or lamotrigine for absence seizures in children and adolescents 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found